Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer

ACS Chemical Biology

Volumn 10, Issue 12, 2015, Pages 2680-2686

  Sumi, Natalia J ^a,b   Kuenzi, Brent M ^a,b   Knezevic, Claire E ^a   Remsing Rix, Lily L ^a   Rix, Uwe ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABEMACICLIB; AURORA A KINASE; CASEIN KINASE II; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE 9; CYCLIN G; IBRUTINIB; PALBOCICLIB; RIBOCICLIB; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; PYRIDINE DERIVATIVE;

ARTICLE; AUTOPHAGY; BINDING COMPETITION; CONTROLLED STUDY; DRUG MECHANISM; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MANTLE CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TARGETING; PROTEOMICS; SQUAMOUS CELL LUNG CARCINOMA; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENZYMOLOGY; LUNG NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AMINOPYRIDINES; ANTINEOPLASTIC AGENTS; AUTOPHAGY; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; MOLECULAR STRUCTURE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEOMICS; PURINES; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 84952838295     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.5b00368     Document Type: Article

References (29)

1. Asghar, U., Witkiewicz, A. K., Turner, N. C., and Knudsen, E. S. (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy Nat. Rev. Drug Discovery 14, 130-146 10.1038/nrd4504
2. Dickson, M. A. (2014) Molecular pathways: CDK4 inhibitors for cancer therapy Clin. Cancer Res. 20, 3379-3383 10.1158/1078-0432.CCR-13-1551
3. Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., Shparyk, Y., Thummala, A. R., Voytko, N. L., Fowst, C., Huang, X., Kim, S. T., Randolph, S., and Slamon, D. J. (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol. 16, 25-35 10.1016/S1470-2045(14)71159-3
4. Herbst, R. S., Gandara, D. R., Hirsch, F. R., Redman, M. W., LeBlanc, M., Mack, P. C., Schwartz, L. H., Vokes, E., Ramalingam, S. S., Bradley, J. D., Sparks, D., Zhou, Y., Miwa, C., Miller, V. A., Yelensky, R., Li, Y., Allen, J. D., Sigal, E. V., Wholley, D., Sigman, C. C., Blumenthal, G. M., Malik, S., Kelloff, G. J., Abrams, J. S., Blanke, C. D., and Papadimitrakopoulou, V. A. (2015) Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 Clin. Cancer Res. 21, 1514-1524 10.1158/1078-0432.CCR-13-3473
5. Hammerman, P. S., Lawrence, M.S., Voet, D., Jing, R., Cibulskis, K., Sivachenko, A., Stojanov, P., McKenna, A., Lander, E.S., and Gabriel, S. et al. 2012, Comprehensive genomic characterization of squamous cell lung cancers Nature 489, 519-525 10.1038/nature11404
6. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., Reader, V., Sweetman, G., Bauer, A., Bouwmeester, T., Hopf, C., Kruse, U., Neubauer, G., Ramsden, N., Rick, J., Kuster, B., and Drewes, G. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat. Biotechnol. 25, 1035-1044 10.1038/nbt1328
7. Godl, K., Wissing, J., Kurtenbach, A., Habenberger, P., Blencke, S., Gutbrod, H., Salassidis, K., Stein-Gerlach, M., Missio, A., Cotten, M., and Daub, H. (2003) An efficient proteomics method to identify the cellular targets of protein kinase inhibitors Proc. Natl. Acad. Sci. U. S. A. 100, 15434-15439 10.1073/pnas.2535024100
8. Ong, S. E., Schenone, M., Margolin, A. A., Li, X., Do, K., Doud, M. K., Mani, D. R., Kuai, L., Wang, X., Wood, J. L., Tolliday, N. J., Koehler, A. N., Marcaurelle, L. A., Golub, T. R., Gould, R. J., Schreiber, S. L., and Carr, S. A. (2009) Identifying the proteins to which small-molecule probes and drugs bind in cells Proc. Natl. Acad. Sci. U. S. A. 106, 4617-4622 10.1073/pnas.0900191106
9. Winter, G. E., Rix, U., Carlson, S. M., Gleixner, K. V., Grebien, F., Gridling, M., Muller, A. C., Breitwieser, F. P., Bilban, M., Colinge, J., Valent, P., Bennett, K. L., White, F. M., and Superti-Furga, G. (2012) Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML Nat. Chem. Biol. 8, 905-912 10.1038/nchembio.1085
10. Li, J., Rix, U., Fang, B., Bai, Y., Edwards, A., Colinge, J., Bennett, K. L., Gao, J., Song, L., Eschrich, S., Superti-Furga, G., Koomen, J., and Haura, E. B. (2010) A chemical and phosphoproteomic characterization of dasatinib action in lung cancer Nat. Chem. Biol. 6, 291-299 10.1038/nchembio.332
11. Remsing Rix, L. L., Kuenzi, B. M., Luo, Y., Remily-Wood, E., Kinose, F., Wright, G., Li, J., Koomen, J. M., Haura, E. B., Lawrence, H. R., and Rix, U. (2014) GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells ACS Chem. Biol. 9, 353-358 10.1021/cb400660a
12. Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., Del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., Neubauer, B. L., Young, J., Chan, E. M., Iversen, P., Cronier, D., Kreklau, E., and de Dios, A. (2014) Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine Invest. New Drugs 32, 825-837 10.1007/s10637-014-0120-7
13. Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., and Toogood, P. L. (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts Mol. Cancer Ther 3, 1427-1438
14. Rader, J., Russell, M. R., Hart, L. S., Nakazawa, M. S., Belcastro, L. T., Martinez, D., Li, Y., Carpenter, E. L., Attiyeh, E. F., Diskin, S. J., Kim, S., Parasuraman, S., Caponigro, G., Schnepp, R. W., Wood, A. C., Pawel, B., Cole, K. A., and Maris, J. M. (2013) Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma Clin. Cancer Res. 19, 6173-6182 10.1158/1078-0432.CCR-13-1675
15. Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., and O'Dwyer, P. J. (2011) Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1) Br. J. Cancer 104, 1862-1868 10.1038/bjc.2011.177
16. Nguyen, L., Zhong, W. Z., Painter, C. L., Zhang, C., Rahavendran, S. V., and Shen, Z. (2010) Quantitative analysis of PD 0332991 in xenograft mouse tumor tissue by a 96-well supported liquid extraction format and liquid chromatography/mass spectrometry J. Pharm. Biomed. Anal. 53, 228-234 10.1016/j.jpba.2010.02.031
17. Rix, U. and Superti-Furga, G. (2009) Target profiling of small molecules by chemical proteomics Nat. Chem. Biol. 5, 616-624 10.1038/nchembio.216
18. Lu, H. and Schulze-Gahmen, U. (2006) Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition J. Med. Chem. 49, 3826-3831 10.1021/jm0600388
19. Remsing Rix, L. L., Rix, U., Colinge, J., Hantschel, O., Bennett, K. L., Stranzl, T., Muller, A., Baumgartner, C., Valent, P., Augustin, M., Till, J. H., and Superti-Furga, G. (2009) Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells Leukemia 23, 477-485 10.1038/leu.2008.334
20. Gridling, M., Ficarro, S. B., Breitwieser, F. P., Song, L., Parapatics, K., Colinge, J., Haura, E. B., Marto, J. A., Superti-Furga, G., Bennett, K. L., and Rix, U. (2014) Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics Mol. Cancer Ther. 13, 2751-2762 10.1158/1535-7163.MCT-14-0152
21. Levine, B. and Kroemer, G. (2008) Autophagy in the pathogenesis of disease Cell 132, 27-42 10.1016/j.cell.2007.12.018
22. Stack, J. H., DeWald, D. B., Takegawa, K., and Emr, S. D. (1995) Vesicle-mediated protein transport: regulatory interactions between the Vps15 protein kinase and the Vps34 PtdIns 3-kinase essential for protein sorting to the vacuole in yeast J. Cell Biol. 129, 321-334 10.1083/jcb.129.2.321
23. Stack, J. H., Herman, P. K., Schu, P. V., and Emr, S. D. (1993) A membrane-associated complex containing the Vps15 protein kinase and the Vps34 PI 3-kinase is essential for protein sorting to the yeast lysosome-like vacuole EMBO J. 12, 2195-2204
24. Emerling, B. M., Hurov, J. B., Poulogiannis, G., Tsukazawa, K. S., Choo-Wing, R., Wulf, G. M., Bell, E. L., Shim, H. S., Lamia, K. A., Rameh, L. E., Bellinger, G., Sasaki, A. T., Asara, J. M., Yuan, X., Bullock, A., Denicola, G. M., Song, J., Brown, V., Signoretti, S., and Cantley, L. C. (2013) Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors Cell 155, 844-857 10.1016/j.cell.2013.09.057
25. Chiron, D., Di Liberto, M., Martin, P., Huang, X., Sharman, J., Blecua, P., Mathew, S., Vijay, P., Eng, K., Ali, S., Johnson, A., Chang, B., Ely, S., Elemento, O., Mason, C. E., Leonard, J. P., and Chen-Kiang, S. (2014) Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma Cancer Discovery 4, 1022-1035 10.1158/2159-8290.CD-14-0098
26. Liang, J., Shao, S. H., Xu, Z. X., Hennessy, B., Ding, Z., Larrea, M., Kondo, S., Dumont, D. J., Gutterman, J. U., Walker, C. L., Slingerland, J. M., and Mills, G. B. (2007) The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis Nat. Cell Biol. 9, 218-224 10.1038/ncb1537
27. Matsumoto, G., Wada, K., Okuno, M., Kurosawa, M., and Nukina, N. (2011) Serine 403 phosphorylation of p62/SQSTM1 regulates selective autophagic clearance of ubiquitinated proteins Mol. Cell 44, 279-289 10.1016/j.molcel.2011.07.039
28. Liu, J., Xia, H., Kim, M., Xu, L., Li, Y., Zhang, L., Cai, Y., Norberg, H. V., Zhang, T., Furuya, T., Jin, M., Zhu, Z., Wang, H., Yu, J., Li, Y., Hao, Y., Choi, A., Ke, H., Ma, D., and Yuan, J. (2011) Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13 Cell 147, 223-234 10.1016/j.cell.2011.08.037
29. Dittmann, A., Werner, T., Chung, C. W., Savitski, M. M., Falth Savitski, M., Grandi, P., Hopf, C., Lindon, M., Neubauer, G., Prinjha, R. K., Bantscheff, M., and Drewes, G. (2014) The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains ACS Chem. Biol. 9, 495-502 10.1021/cb400789e